The biotech industry has changed significantly over the last few years. Capital is more expensive, regulatory expectations have increased, and investors are placing greater emphasis on efficiency, measurable milestones, and long-term value creation.
The New Rules of Biotech explains why founders must rethink the traditional company-building process. From selecting the right scientific strategy to securing funding and advancing clinical development, every stage now requires a more disciplined and strategic approach.
Rather than relying on outdated assumptions, the book provides a modern operating framework that helps founders make better decisions while giving investors and advisors a clearer understanding of today’s biotech landscape.